文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

中国广西未治疗HIV-1感染者衣壳抑制剂耐药及亚型分布的近全长基因组NGS评估

Evaluation of capsid inhibitor resistance profiles and HIV-1 subtype distribution via near-full-length genome NGS in ART-naive HIV-1 patients in Guangxi, China.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

研究采用NGS对广西495例未接受抗病毒治疗的HIV-1感染者血浆标本进行近全长基因组测序,在5%频率阈值下检测衣壳抑制剂耐药突变。4.44%序列携带至少一种衣壳抑制剂耐药突变,包括主要突变Q67H(0.80%)及辅助突变T107A(2.22%)和T107S(1.81%),且未观察到与其他药物类别的交叉耐药;Q67H和T107S为CRF01_AE亚型特异性多态性,T107A和T107S为CRF08_Bc亚型特异性多态性。

要点

  • 未治疗感染者中衣壳抑制剂耐药突变以辅助突变T107A/T107S为主,主要突变Q67H罕见。
  • 衣壳抑制剂耐药突变未伴随对PI、NRTI、NNRTI或INSTI的交叉耐药。
  • 常规部分pol基因分型易误判独特重组型,建议本地加强全基因组基因型监测。

核心结论

  • 广西未治疗HIV-1感染者中存在自然发生的衣壳抑制剂相关耐药突变,且以亚型特异性多态性形式呈现。

研究设计与样本

  • 采用NGS对广西495例未接受抗病毒治疗个体的血浆标本进行近全长基因组测序,以5%频率阈值调用变异。

主要发现

  • 495例中16.77%(83/495)感染独特重组型。
  • 4.44%(22/495)序列携带至少一种衣壳抑制剂耐药突变,包括Q67H(0.80%)、T107A(2.22%)和T107S(1.81%)。
  • 携带衣壳抑制剂耐药突变的个体未观察到对PI、NRTI、NNRTI或INSTI的交叉耐药。
  • 按>0.5%流行率定义亚型特异性多态性,Q67H(1.60%,3/188)和T107S(1.60%,3/188)为CRF01_AE特异性,T107A(5.05%,11/218)和T107S(3.03%,5/218)为CRF08_Bc特异性。

关键数值与推荐

  • 变异调用频率阈值为5%,亚型特异性多态性流行率截断值为0.5%。

临床怎么用

  • 对未治疗HIV-1感染者进行衣壳抑制剂耐药监测时,应考虑亚型特异性多态性对耐药判读的影响。
  • 在独特重组型常见地区,建议采用近全长基因组测序以提升亚型分型的准确性。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Lenacapavir, a first-in-class, long-acting capsid inhibitor (CAI), has been approved for HIV-1 treatment and prevention. However, naturally occurring resistance to the HIV-1 CAI at the quasi-species level is rarely reported. METHODS: Using next-generation sequencing (NGS), we obtained 495 HIV-1 near-full-length genome (NFLG) sequences derived from plasma specimens of ART-naive individuals in Guangxi, China. Drug resistance mutations (DRMs) conferring resistance to CAIs, as well as to NNRTIs, NRTIs, PIs and INSTIs, were detected at a 5% frequency threshold for variant calling using the HIVdb program. To analyse naturally occurring polymorphisms, the gag sequences of CRF08_Bc subtype were retrieved from two public sequence databases, followed by CAI-related DRM detection. Subtype-specific capsid polymorphism was analysed with a 0.5% prevalence cut-off. RESULTS: Of the 495 individuals, 16.77% (83/495) were infected with unique recombinant forms (URFs). Overall, 4.44% (22/495) of the sequences were carrying at least DRMs to CAIs, including one major DRM (Q67H, 0.80%) and two accessory DRMs (T107A, 2.22%; T107S, 1.81%). No cross-resistance to other classes of drugs, including PIs, NRTIs, NNRTIs or INSTIs, was observed in individuals with CAI-related DRMs. According to the definition of subtype-specific polymorphism (>0.5% prevalence), Q67H (1.60%, 3/188) and T107S (1.60%, 3/188) were CRF01_AE-specific polymorphisms, whereas T107A (5.05%, 11/218) and T107S (3.03%, 5/218) were CRF08_Bc-specific polymorphisms. CONCLUSIONS: HIV URFs are commonly misclassified by conventional partial pol gene subtyping among treatment-naive patients in Guangxi, indicating a need for enhanced full-genome genotyping surveillance locally. Subtype-specific capsid polymorphisms that have not been identified in previous studies further highlight the value of geographically diverse cohorts in future CAI research to improve real-world applicability.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Pan P, Mo C, Chen R, et al. Evaluation of capsid inhibitor resistance profiles and HIV-1 subtype distribution via near-full-length genome NGS in ART-naive HIV-1 patients in Guangxi, China. J Antimicrob Chemother. 2026. PMID: 42948969. doi:10.1093/jac/dkag334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。